Fennec Pharmaceuticals Inc (FENC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $410.25M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fennec Pharmaceuticals Inc (FENC) Earnings: Report Dates and Results
Fennec Pharmaceuticals (FENC) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Fennec Pharmaceuticals reported EPS of $0.12, above the $0.09 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
FENC has an expected report date of Mar 22, 2027.
FENC Earnings Call
The latest FENC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 36 quarters below that had an estimate, FENC beat 11, missed 20 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $19.61M, up 57.4% from $12.46M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.12 | $0.09 | $0.06 - $0.16 | +33.33% | Beat | N/A | 5 | 1 up, 2 down | Nov 12, 2026 | $19.61M |
| Jun 30, 2026 | $0.05 | $0.01 | $0.00 - $0.05 | +400.00% | Beat | N/A | 5 | 0 up, 2 down | Aug 11, 2026 | $17.87M |
| Mar 31, 2026 | $0.01 | $0.03 | -$0.13 - $0.11 | -70.24% | Miss | N/A | 6 | 0 up, 5 down | May 14, 2026 | $15.11M |
| Dec 31, 2025 | -$0.10 | $0.04 | -$0.01 - $0.06 | -350.00% | Miss | N/A | 5 | 0 up, 0 down | Mar 24, 2026 | $13.78M |
| Sep 30, 2025 | -$0.02 | -$0.02 | -$0.09 - $0.04 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 13, 2025 | $12.46M |
| Jun 30, 2025 | -$0.11 | -$0.03 | -$0.07 - $0.00 | -266.67% | Miss | N/A | 4 | 1 up, 0 down | Aug 14, 2025 | $9.65M |
| Mar 31, 2025 | -$0.04 | -$0.08 | -$0.13 - -$0.05 | +50.00% | Beat | -109.8% | 4 | 2 up, 1 down | May 13, 2025 | $8.75M |
| Dec 31, 2024 | -$0.06 | -$0.13 | -$0.19 - -$0.09 | +53.85% | Beat | N/A | 4 | 1 up, 0 down | Mar 10, 2025 | $7.92M |
| Sep 30, 2024 | -$0.21 | -$0.08 | -$0.14 - -$0.02 | -162.50% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2024 | $6.97M |
| Jun 30, 2024 | -$0.20 | $0.02 | -$0.24 - $0.42 | N/A | N/A | N/A | 6 | 0 up, 0 down | Aug 13, 2024 | $7.26M |
| Mar 31, 2024 | $0.41 | -$0.04 | -$0.08 - $1.54 | N/A | N/A | N/A | 5 | 0 up, 0 down | May 14, 2024 | $25.38M |
| Dec 31, 2023 | -$0.10 | -$0.02 | -$0.10 - $0.03 | -400.00% | Miss | N/A | 5 | 1 up, 0 down | Mar 21, 2024 | $9.73M |
| Sep 30, 2023 | -$0.07 | -$0.13 | -$0.15 - -$0.07 | +46.15% | Beat | N/A | 6 | 0 up, 0 down | Nov 6, 2023 | $6.51M |
| Jun 30, 2023 | -$0.21 | -$0.16 | -$0.20 - -$0.09 | -31.25% | Miss | N/A | 6 | 0 up, 0 down | Aug 3, 2023 | $3.33M |
| Mar 31, 2023 | -$0.23 | -$0.19 | N/A | -21.05% | Miss | N/A | 5 | 1 up, 0 down | May 11, 2023 | $1.68M |
| Dec 31, 2022 | -$0.26 | -$0.26 | -$0.33 - -$0.17 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Mar 30, 2023 | $1.53M |
| Sep 30, 2022 | -$0.31 | -$0.19 | -$0.22 - -$0.14 | -63.16% | Miss | N/A | 6 | 0 up, 0 down | Nov 11, 2022 | N/A |
| Jun 30, 2022 | -$0.19 | -$0.13 | -$0.16 - -$0.11 | -46.15% | Miss | N/A | 3 | 0 up, 1 down | Aug 12, 2022 | N/A |
| Mar 31, 2022 | -$0.14 | -$0.14 | -$0.15 - -$0.13 | 0.00% | In line | N/A | 2 | 1 up, 0 down | May 12, 2022 | N/A |
| Dec 31, 2021 | -$0.18 | $0.75 | -$0.20 - $3.52 | -124.00% | Miss | N/A | 4 | 0 up, 0 down | Feb 28, 2022 | N/A |
| Sep 30, 2021 | -$0.16 | -$0.14 | N/A | -14.29% | Miss | N/A | 4 | 4 up, 0 down | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$0.15 | -$0.18 | -$0.20 - -$0.17 | +16.67% | Beat | N/A | 5 | N/A | Aug 10, 2021 | N/A |
| Mar 31, 2021 | -$0.19 | -$0.38 | N/A | +50.00% | Beat | N/A | 2 | N/A | May 13, 2021 | N/A |
| Dec 31, 2020 | -$0.13 | -$0.19 | -$0.19 - -$0.19 | +31.58% | Beat | N/A | 1 | N/A | Mar 30, 2021 | $170000 |
| Sep 30, 2020 | -$0.24 | -$0.19 | -$0.21 - -$0.16 | -26.32% | Miss | N/A | 3 | N/A | Nov 16, 2020 | N/A |
| Jun 30, 2020 | -$0.21 | -$0.17 | -$0.22 - -$0.15 | -23.53% | Miss | N/A | 3 | N/A | Aug 5, 2020 | N/A |
| Mar 31, 2020 | -$0.19 | -$0.18 | -$0.21 - -$0.17 | -5.56% | Miss | N/A | 3 | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | -$0.18 | -$0.11 | -$0.16 - -$0.10 | -63.64% | Miss | N/A | 3 | N/A | Feb 14, 2020 | N/A |
| Sep 30, 2019 | -$0.09 | -$0.19 | -$0.26 - -$0.13 | +52.63% | Beat | N/A | 3 | N/A | Nov 12, 2019 | N/A |
| Jun 30, 2019 | -$0.24 | -$0.13 | -$0.15 - -$0.13 | -84.62% | Miss | N/A | 3 | N/A | Aug 9, 2019 | N/A |
| Mar 31, 2019 | -$0.13 | -$0.14 | -$0.19 - -$0.13 | +7.14% | Beat | N/A | 3 | N/A | May 9, 2019 | N/A |
| Dec 31, 2018 | -$0.15 | -$0.14 | -$0.17 - -$0.10 | -7.14% | Miss | N/A | 3 | N/A | Mar 13, 2019 | N/A |
| Sep 30, 2018 | -$0.14 | -$0.14 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 13, 2018 | N/A |
| Jun 30, 2018 | -$0.14 | -$0.09 | N/A | -55.56% | Miss | N/A | N/A | N/A | Aug 13, 2018 | N/A |
| Mar 31, 2018 | -$0.09 | -$0.11 | N/A | +18.18% | Beat | N/A | N/A | N/A | May 14, 2018 | N/A |
| Dec 31, 2017 | -$0.14 | -$0.14 | N/A | 0.00% | In line | N/A | 1 | N/A | Mar 26, 2018 | N/A |
| Sep 30, 2017 | -$0.15 | -$0.04 | N/A | -275.00% | Miss | N/A | N/A | N/A | Nov 13, 2017 | N/A |
| Jun 30, 2017 | -$0.11 | -$0.05 | N/A | -120.00% | Miss | N/A | N/A | N/A | Aug 11, 2017 | N/A |
| Mar 31, 2017 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2017 | N/A |
| Sep 30, 2016 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.27, after -$0.06 the year before. It was -$0.06 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.27 | N/A |
| Dec 31, 2024 | -$0.06 | N/A |
| Dec 31, 2023 | -$0.61 | N/A |
| Dec 31, 2022 | -$0.90 | N/A |
| Dec 31, 2021 | -$0.68 | N/A |
| Dec 31, 2020 | -$0.77 | N/A |
| Dec 31, 2019 | -$0.64 | N/A |
| Dec 31, 2018 | -$0.52 | N/A |
| Dec 31, 2017 | -$0.61 | N/A |
| Dec 31, 2015 | -$0.06 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,900 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,905 | 7 | |
| 2026Q2 | Jun 30, 2026 | 5,507 | 9 | |
| 2026Q1 | Mar 31, 2026 | 4,773 | 10 | |
| 2025Q4 | Dec 31, 2025 | 6,683 | 9 | |
| 2025Q2 | Jun 30, 2025 | 4,990 | 6 | |
| 2025Q1 | Mar 31, 2025 | 4,614 | 7 | |
| 2024Q4 | Dec 31, 2024 | 4,597 | 7 | |
| 2024Q3 | Sep 30, 2024 | 3,321 | 5 |
2026Q3 Earnings Call
Opening remarks
Robert C. Andrade CFO Thank you, operator, and good morning, everyone. Thank you for joining us. We are pleased to host Fennec Pharmaceuticals' third quarter 2026 earnings conference call today, during which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is our chief executive officer and board member, Jeffrey S. Hackman. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. References to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on our website, www.fennecpharma.com, where it will be available for the next 30 days. And with that, I will now turn the call over to Jeffrey S. Hackman.
Jeffrey S. Hackman CEO Thank you, Robert, and good morning, everyone. Thank you for joining us here today. We are pleased to report yet another quarter of revenue growth, reflecting continued progress across our business and the positive momentum that we are building around PEDMARK. As we look ahead, we remain focused on executing our commercial strategy, strengthening the evidence supporting the use of PEDMARK, and expanding opportunities to reach more patients who may benefit from this treatment. Today, I would like to highlight two significant areas of progress from the quarter. First, we are realizing the benefits of the investments that we made in Project Ignite, which is a strategic expansion of our sales organization. We made this investment in the first quarter of the year. We invested in 14 territories and four frontline managers to expand our ability to engage healthcare professionals, support the adoption of our product, and strengthen our commercial presence across priority markets. We now have two full quarters in the field with our new territory managers, and they are delivering productivity gains. Greater efficiency is enabling us to reach more healthcare professionals and engage them more frequently across our targeted segments. We are seeing strong uptake in the community with oncologists, and we remain focused on accelerating adoption at academic centers. This momentum is strengthening our presence and relationships across these new and existing accounts.
Frequently Asked Questions About FENC
When is Fennec Pharmaceuticals's next earnings date?
Fennec Pharmaceuticals's next earnings report is expected for Mar 22, 2027.
Did FENC beat earnings estimates last quarter?
Yes. Fennec Pharmaceuticals reported EPS of $0.12 for the quarter ended Sep 30, 2026, above the $0.09 estimate, a 33.33% surprise.
What EPS do analysts expect from FENC next quarter?
The consensus EPS estimate for Fennec Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.15 from 8 analysts, with estimates from $0.09 to $0.24.
How often does FENC beat earnings estimates?
Fennec Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -18.72%.
FENC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors